Although detectable via IHC with four FDA authorized diagnostic tests—22C3, 28-8, SP142, and SP263—the evaluation of PD-L1 expression employs IHC indicators such as the combined positive score (CPS) and tumor proportion score (TPS). This evidence concerns the gene CD274 and neoplasm.